Search academic texts

Information × Registration Number 0213U000541, 0111U000377 , R & D reports Title Developing of the maintenance therapy in breast cancer patients who receive chemotherapy, considering clinical and laboratory of toxicity prognosis factors popup.stage_title Head Syvak Liubov, Registration Date 14-02-2013 Organization Ukrainian Research Institute of Oncology and Radiology popup.description2 The object of study - 130 patients with malignant breast tumors with toxic effects of chemotherapy regimen FAC. Purpose - to improve the results of chemotherapy and quality of life in patients with malignant breast tumors by developing maintenance therapy based on the clinical and laboratory prediction factors of toxicity of anticancer drugs. Methods and apparatus: clinical, laboratory, instrumental, statistical, ultrasound machine "Aloca", hematology analyzer BC-3000 biochemical analyzer "Vitros", spectrophotometer "Thermo", a high-speed centrifuge "Biofuge", Thermostat "Termyt." As a result of clinical (complaints, physical data), laboratory (hemogram with differential count and erythrocyte sedimentation rate, blood chemistries, urinalysis), instrumental (ECG, echocardiography, chest cavity, abdominal ultrasound or computed tomography chest, abdomen and pelvis with contrast enhancement) research and analysis of molecular genetic parameters (gene polymorphism GSTP1, MTHFR, protein expression ITSN2) during chemotherapy regimen FAC (4-6 cycles) in patients with malignant breast tumors found that the regimen has a moderate (II-III) toxicity rate, the main manifestations of which are gastrointestinal (95.4%), cardiovascular (16.1%) and hematological (1.6%) toxicity. The most important prognostic factors for chemotherapy toxicity regimen FAC in patients with malignant breast tumors include age over 45 years, concomitant diseases, especially cardiovascular system and gastrointestinal tract, cancerstage, previous anticancer treatment and the presence of the mutant allele G gene GSTP1 and T allele of the gene MTHFR. Algorithm of the support therapy implementation in patients with malignant breast tumors with a high risk of complications allowed to perform chemotherapy timely, reduce the appearance of gastrointestinal toxicity in 80.5% and early cardiotoxicity - in 56.2% patient. Quality of life and outcomeswere also improved. Field of implementation: oncology. Product Description popup.authors Алексик Олена Олексіївна Аскольський Антон Вячеславович Губарева Ганна Олександрівна Кліманов Михайло Юрійович Лялькін Сергій Анатолійович Майданевич Наталя Миколаївна Свергун Наталя Миколаївна Сивак Любов Андріївна Філоненко Катерина Сергіївна Шевчук Леся Анатоліївна popup.nrat_date 2020-04-02 Close